… Lung cancer remains the leading cause of cancer death globally, and outcomes for patients
diagnosed with advanced non-small-cell lung cancer are poor despite recent advances in …

… Non-small-cell lung cancer (NSCLC) with EGFR mutations represents a molecularly distinct
type of lung cancer with established first-line treatment options; these include the EGFR-…

… In this phase 2, multicentre, non-randomised, open-label study, we enrolled previously
treated and untreated patients with stage IV metastatic BRAF V600E -positive NSCLC. Patients …

Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged
non-small-cell lung cancer (NSCLC) is not known. We assessed the …

… cell lung cancer (NSCLC) remains a leading cause of cancer-… molecular pathogenesis of
lung cancer. Activating mutations … of molecular pathogenesis in lung cancer, which has led to a …

Background Treatments for small-cell lung cancer (SCLC) after failure of platinum-based
chemotherapy are limited. We assessed safety and activity of nivolumab and nivolumab plus …

… -cell lung cancer centrally using an interactive voice response system (IVRS) in a ratio of
1:1 to chemotherapy plus cetuximab or chemotherapy alone in a multinational, open-label, …

… for patients with squamous cell lung cancers (SQCLC) have largely failed, despite relatively
detailed knowledge of the somatic events that occur in these cancers. The reasons for this …

Background Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally
advanced stage disease. We aimed to assess the antitumour activity and safety of neoadjuvant …

Background Nivolumab has shown improved survival in the treatment of advanced non-small-cell
lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety …